FARN:LON
Faron Pharmaceuticals Oy
GBX 36.75
arrow_upward
+0.68%(+0.25) 1 日
10月8日, 16:30:00 GMT+1 · GBX
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoFARN の上位の分析情報を生成しています...
始値
GBX 35.10
高値
GBX 37.90
安値
GBX 35.06
時価総額
7463.05万
平均出来高
4.90万
取引量
2.05万
52 週高値
GBX 193.58
52 週安値
GBX 34.00
EPS
-GBX 0.10
発行済株式数
3102.79万
従業員数
36
始値
GBX 35.10
高値
GBX 37.90
安値
GBX 35.06
時価総額
7463.05万
平均出来高
4.90万
取引量
2.05万
52 週高値
GBX 193.58
52 週安値
GBX 34.00
EPS
-GBX 0.10
発行済株式数
3102.79万
従業員数
36
ニュース記事
情報源: ウェブソース、ニュース パートナー
marketscreener.com
·
17 時間前
Faron agrees bond repayment deferrals for more financial flexibility
プロフィール
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Faron Pharmaceuticals Oy について